

James M Markert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1176619/publications.pdf>

Version: 2024-02-01

70
papers

3,963
citations

147801

31
h-index

123424

61
g-index

71
all docs

71
docs citations

71
times ranked

3373
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting High-Risk Neuroblastoma Patient-Derived Xenografts with Oncolytic Virotherapy. <i>Cancers</i> , 2022, 14, 762.	3.7	7
2	Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study. <i>Clinical Cancer Research</i> , 2022, 28, 498-506.	7.0	12
3	Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial. <i>Neuro-Oncology Advances</i> , 2022, 4, vdab186.	0.7	1
4	Safety and interim survival data after intracranial administration of M032, a genetically engineered oncolytic HSV-1 expressing IL-12, in pet dogs with sporadic gliomas. <i>Neurosurgical Focus</i> , 2021, 50, E5.	2.3	20
5	Immunovirotherapy for the Treatment of Glioblastoma and Other Malignant Gliomas. <i>Neurosurgery Clinics of North America</i> , 2021, 32, 265-281.	1.7	14
6	Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas. <i>New England Journal of Medicine</i> , 2021, 384, 1613-1622.	27.0	173
7	Commentary: Developing a Professionalism and Harassment Policy for Organized Neurosurgery. <i>Neurosurgery</i> , 2021, 89, E60-E60.	1.1	0
8	Positron emission tomography imaging with 89Zr-labeled anti-CD8 cys-diabody reveals CD8+ cell infiltration during oncolytic virus therapy in a glioma murine model. <i>Scientific Reports</i> , 2021, 11, 15384.	3.3	13
9	Design and Rationale for First-in-Human Phase 1 Immunovirotherapy Clinical Trial of Oncolytic HSV G207 to Treat Malignant Pediatric Cerebellar Brain Tumors. <i>Human Gene Therapy</i> , 2020, 31, 1132-1139.	2.7	24
10	The One Health Consortium: Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Combination With a Checkpoint Inhibitor in Canine Patients With Sporadic High Grade Gliomas. <i>Frontiers in Surgery</i> , 2020, 7, 59.	1.4	5
11	Current and Future Imaging Methods for Evaluating Response to Immunotherapy in Neuro-Oncology. <i>Theranostics</i> , 2019, 9, 5085-5104.	10.0	29
12	Oncolytic herpes simplex virus immunotherapy for brain tumors: current pitfalls and emerging strategies to overcome therapeutic resistance. <i>Oncogene</i> , 2019, 38, 6159-6171.	5.9	45
13	A novel in situ multiplex immunofluorescence panel for the assessment of tumor immunopathology and response to virotherapy in pediatric glioblastoma reveals a role for checkpoint protein inhibition. <i>Oncotarget</i> , 2019, 8, e1678921.	4.6	18
14	Diagnosing growth in low-grade gliomas with and without longitudinal volume measurements: A retrospective observational study. <i>PLoS Medicine</i> , 2019, 16, e1002810.	8.4	13
15	Stereotactic Placement of Intratumoral Catheters for Continuous Infusion Delivery of Herpes Simplex Virus -1 G207 in Pediatric Malignant Supratentorial Brain Tumors. <i>World Neurosurgery</i> , 2019, 122, e1592-e1598.	1.3	17
16	Characterization of iPSCs derived from low grade gliomas revealed early regional chromosomal amplifications during gliomagenesis. <i>Journal of Neuro-Oncology</i> , 2019, 141, 289-301.	2.9	11
17	Chimeric HCMV/HSV-1 and $\hat{\mu}$ ³ 134.5 oncolytic herpes simplex virus elicit immune mediated antiglioma effect and antitumor memory. <i>Translational Oncology</i> , 2018, 11, 86-93.	3.7	24
18	Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression. <i>Scientific Reports</i> , 2018, 8, 13930.	3.3	56

#	ARTICLE	IF	CITATIONS
19	Oncolytic Virotherapy for the Treatment of Malignant Glioma. <i>Neurotherapeutics</i> , 2017, 14, 333-344.	4.4	108
20	Pre-clinical Assessment of C134, a Chimeric Oncolytic Herpes Simplex Virus, in Mice and Non-human Primates. <i>Molecular Therapy - Oncolytics</i> , 2017, 5, 1-10.	4.4	33
21	Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors. <i>Human Gene Therapy Clinical Development</i> , 2017, 28, 7-16.	3.1	45
22	Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002. <i>Molecular Therapy - Oncolytics</i> , 2017, 7, 27-36.	4.4	13
23	Modulation of the Intratumoral Immune Landscape by Oncolytic Herpes Simplex Virus Virotherapy. <i>Frontiers in Oncology</i> , 2017, 7, 136.	2.8	40
24	Combination strategies enhance oncolytic virotherapy. <i>Oncotarget</i> , 2017, 8, 34020-34021.	1.8	3
25	To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses. <i>Viruses</i> , 2016, 8, 43.	3.3	36
26	Effect of HSV-IL12 Loaded Tumor Cell-Based Vaccination in a Mouse Model of High-Grade Neuroblastoma. <i>Journal of Immunology Research</i> , 2016, 2016, 1-10.	2.2	14
27	Effect of Repeat Dosing of Engineered Oncolytic Herpes Simplex Virus on Preclinical Models of Rhabdomyosarcoma. <i>Translational Oncology</i> , 2016, 9, 419-430.	3.7	8
28	A phase 2 study of radiosurgery and temozolomide for patients with 1 to 4 brain metastases. <i>Advances in Radiation Oncology</i> , 2016, 1, 83-88.	1.2	4
29	Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. <i>Human Gene Therapy Clinical Development</i> , 2016, 27, 69-78.	3.1	113
30	STAT1 and NF- κ B Inhibitors Diminish Basal Interferon-Stimulated Gene Expression and Improve the Productive Infection of Oncolytic HSV in MPNST Cells. <i>Molecular Cancer Research</i> , 2016, 14, 482-492.	3.4	34
31	Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses. <i>Neuro-Oncology</i> , 2016, 18, 227-235.	1.2	53
32	Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children. <i>Molecular Therapy - Oncolytics</i> , 2015, 2, 15015.	4.4	19
33	Pediatric cancer gone viral. Part II: potential clinical application of oncolytic herpes simplex virus-1 in children. <i>Molecular Therapy - Oncolytics</i> , 2015, 2, 15016.	4.4	11
34	Spontaneous cerebellar hemorrhage in a patient taking apixaban. <i>Interdisciplinary Neurosurgery: Advanced Techniques and Case Management</i> , 2015, 2, 54-56.	0.3	1
35	Preclinical Evaluation of Engineered Oncolytic Herpes Simplex Virus for the Treatment of Pediatric Solid Tumors. <i>PLoS ONE</i> , 2014, 9, e86843.	2.5	10
36	A Phase 1 Trial of Oncolytic HSV-1, G207, Given in Combination With Radiation for Recurrent GBM Demonstrates Safety and Radiographic Responses. <i>Molecular Therapy</i> , 2014, 22, 1048-1055.	8.2	233

#	ARTICLE	IF	CITATIONS
37	Phase 1 Clinical Trial of Intratumoral Reovirus Infusion for the Treatment of Recurrent Malignant Gliomas in Adults. <i>Molecular Therapy</i> , 2014, 22, 1056-1062.	8.2	119
38	Hypofractionated stereotactic radiosurgery with concurrent bevacizumab for recurrent malignant gliomas: the University of Alabama at Birmingham experience. <i>Neuro-Oncology Practice</i> , 2014, 1, 172-177.	1.6	13
39	Evaluation of the Safety and Biodistribution of M032, an Attenuated Herpes Simplex Virus Type 1 Expressing hIL-12, After Intracerebral Administration to Aotus Nonhuman Primates. <i>Human Gene Therapy Clinical Development</i> , 2014, 25, 16-27.	3.1	59
40	Histone Deacetylase Inhibitors Improve the Replication of Oncolytic Herpes Simplex Virus in Breast Cancer Cells. <i>PLoS ONE</i> , 2014, 9, e92919.	2.5	48
41	Pediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapy. <i>Frontiers in Oncology</i> , 2013, 3, 28.	2.8	11
42	Prognostic Relevance of Cytochrome c Oxidase in Primary Glioblastoma Multiforme. <i>PLoS ONE</i> , 2013, 8, e61035.	2.5	39
43	Preclinical Evaluation of Engineered Oncolytic Herpes Simplex Virus for the Treatment of Neuroblastoma. <i>PLoS ONE</i> , 2013, 8, e77753.	2.5	21
44	Preclinical Evaluation of a Genetically Engineered Herpes Simplex Virus Expressing Interleukin-12. <i>Journal of Virology</i> , 2012, 86, 5304-5313.	3.4	68
45	Preclinical Evaluation of Oncolytic HSV-1 Expressing Interleukin-12 for Therapy of Breast Cancer Brain Metastases. <i>International Journal of Breast Cancer</i> , 2012, 2012, 1-12.	1.2	26
46	Stereotactic radiosurgical treatment of brain metastasis of primary tumors that rarely metastasize to the central nervous system. <i>Journal of Neuro-Oncology</i> , 2012, 109, 513-519.	2.9	16
47	Hypoxia Moderates HSV-1 Deleted Herpes Simplex Virus Oncolytic Activity in Human Glioma Xenograft Primary Cultures. <i>Translational Oncology</i> , 2012, 5, 200-207.	3.7	35
48	Preclinical evaluation of ex vivo expanded/activated CD8 ⁺ T cells for immunotherapy of glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2011, 101, 179-188.	2.9	47
49	Acquisition of Temozolomide Chemoresistance in Gliomas Leads to Remodeling of Mitochondrial Electron Transport Chain. <i>Journal of Biological Chemistry</i> , 2010, 285, 39759-39767.	3.4	158
50	Herpes Simplex Virus Oncolytic Therapy for Pediatric Malignancies. <i>Molecular Therapy</i> , 2009, 17, 1125-1135.	8.2	45
51	Phase Ib Trial of Mutant Herpes Simplex Virus G207 Inoculated Pre-and Post-tumor Resection for Recurrent GBM. <i>Molecular Therapy</i> , 2009, 17, 199-207.	8.2	346
52	Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111. <i>Journal of Neuro-Oncology</i> , 2009, 95, 199-209.	2.9	74
53	Oncolytic Viral Therapy of Malignant Glioma. <i>Neurotherapeutics</i> , 2009, 6, 558-569.	4.4	79
54	Predictors of Distant Brain Recurrence for Patients With Newly Diagnosed Brain Metastases Treated With Stereotactic Radiosurgery Alone. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 181-186.	0.8	77

#	ARTICLE	IF	CITATIONS
55	A Phase I Trial of Intratumoral Administration of Reovirus in Patients With Histologically Confirmed Recurrent Malignant Gliomas. <i>Molecular Therapy</i> , 2008, 16, 627-632.	8.2	243
56	Genetically engineered herpes simplex viruses that express IL-12 or GM-CSF as vaccine candidates. <i>Vaccine</i> , 2006, 24, 1644-1652.	3.8	31
57	Serial Passage through Human Glioma Xenografts Selects for a γ 134.5 Herpes Simplex Virus Type 1 Mutant That Exhibits Decreased Neurotoxicity and Prolongs Survival of Mice with Experimental Brain Tumors. <i>Journal of Virology</i> , 2006, 80, 7308-7315.	3.4	20
58	Oncolytic HSV-1 for the treatment of brain tumours. <i>Herpes: the Journal of the IHMF</i> , 2006, 13, 66-71.	0.3	15
59	Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12. <i>Cancer Gene Therapy</i> , 2005, 12, 359-368.	4.6	57
60	Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model. <i>Neuro-Oncology</i> , 2005, 7, 213-224.	1.2	107
61	A Phase I Open-Label, Dose-Escalation, Multi-Institutional Trial of Injection with an E1B-Attenuated Adenovirus, ONYX-015, into the Peritumoral Region of Recurrent Malignant Gliomas, in the Adjuvant Setting. <i>Molecular Therapy</i> , 2004, 10, 958-966.	8.2	401
62	Initial treatment of melanoma brain metastases using gamma knife radiosurgery. <i>Cancer</i> , 2004, 101, 825-833.	4.1	86
63	Biologic warfare for a good cause: HSV-1 anti-tumor therapy. <i>Clinical Neurosurgery</i> , 2004, 51, 73-80.	0.2	1
64	Oncolytic Viruses: Clinical Applications as Vectors for the Treatment of Malignant Gliomas. <i>Journal of Neuro-Oncology</i> , 2003, 65, 203-226.	2.9	113
65	Genetically engineered HSV in the treatment of glioma: a review. , 2000, 10, 17-30.		74
66	Use of the Extreme Lateral Approach in the Surgical Treatment of an Intradural Ventral Cervical Spinal Cord Vascular Malformation: Technical Case Report. <i>Neurosurgery</i> , 1996, 38, 412-415.	1.1	25
67	Reduction and Elimination of Encephalitis in an Experimental Glioma Therapy Model with Attenuated Herpes Simplex Mutants that Retain Susceptibility to Acyclovir. <i>Neurosurgery</i> , 1993, 32, 597-603.	1.1	244
68	Herpesviruses as therapeutic agents. , 0, , 1341-1352.		0
69	Evaluation of the Safety and Biodistribution of M032, an Attenuated HSV-1 Virus Expressing hIL-12, After Intracerebral Administration to Aotus Non-Human Primates. <i>Human Gene Therapy Clinical Development</i> , 0, , 150127063140004.	3.1	3
70	Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. <i>Human Gene Therapy Clinical Development</i> , 0, , .	3.1	2